Claudio Brunstein

Dr. Claudio Brunstein

Transplant Surgery
10201 Carnegie Avenue, 
Cleveland, OH 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
30 Years of Experience
10201 Carnegie Avenue, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Claudio Brunstein is a Transplant Surgeon in Cleveland, Ohio. Dr. Brunstein has been practicing medicine for over 30 years and is rated as an Experienced provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Smoldering Multiple Myeloma, Chronic Graft Versus Host Disease (cGvHD), Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 168 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Not Applicable
Residency
Hospital de Clinicas de Porto Alegre
Specialties
Transplant Surgery
Licenses
Internal Medicine in MN
Board Certifications
American Board Of Internal Medicine, 2017
Fellowships
University of Minnesota
Hospital Affiliations
Cleveland Clinic
Akron General Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Cleveland Clinic Main Campus
10201 Carnegie Avenue, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Enrollment Status: Recruiting
Publish Date: December 18, 2025
Intervention Type: Biological
Study Phase: Not Applicable
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
Enrollment Status: Completed
Publish Date: July 04, 2025
Intervention Type: Radiation, Biological, Drug
Study Drugs: Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus, Anti-Thymocyte Globulin
Study Phase: Phase 2
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Biological
Study Phase: Phase 3
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Biological, Drug
Study Drugs: Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil
Study Phase: Phase 2
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
Enrollment Status: Terminated
Publish Date: March 03, 2025
Intervention Type: Drug
Study Phase: Not Applicable
QUILT-3.033: Haploidentical Donor Natural Killer (NK) Cell Infusion With Subcutaneous ALT-803 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia
QUILT-3.033: Haploidentical Donor Natural Killer (NK) Cell Infusion With Subcutaneous ALT-803 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Biological
Study Phase: Phase 2
View 7 Less Clinical Trials

168 Total Publications

Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 18, 2025
Similar Doctors
Experienced in Chronic Myelogenous Leukemia (CML)
Dr. Brian J. Bolwell
Oncology | Transplant Surgery
Experienced in Chronic Myelogenous Leukemia (CML)
Dr. Brian J. Bolwell
Oncology | Transplant Surgery

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances

Brian Bolwell is a Transplant Surgeon in Cleveland, Ohio. Dr. Bolwell is rated as an Advanced provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Febrile Neutropenia, Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brunstein's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile